These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 10426575

  • 1. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
    Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K.
    Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
    [Abstract] [Full Text] [Related]

  • 2. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P, Díez JJ.
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [Abstract] [Full Text] [Related]

  • 3. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
    Fukuda T, Yokoyama N, Tamai M, Imaizumi M, Kimura H, Tominaga T, Ashizawa K, Kiriyama T, Yoshimine H, Ohishi K, Eguchi K.
    Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 6. A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.
    Erem C, Hacihasanoglu A, Sari A, Onder Ersöz H, Ukinç K, Fidan S.
    Endocrine; 2004 Nov; 25(2):141-5. PubMed ID: 15711028
    [Abstract] [Full Text] [Related]

  • 7. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
    Teramoto A, Sanno N, Tahara S, Osamura YR.
    Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
    [Abstract] [Full Text] [Related]

  • 8. A case of thyrotropin-secreting pituitary microadenoma with normal thyrotropin alpha-subunit level.
    Ozata M, Oztürk E, Narin Y, Tayfun C, Azal O, Beyhan Z, Corakçi A, Bayhan H, Gündoğan MA.
    Thyroid; 1997 Jun; 7(3):441-7. PubMed ID: 9226217
    [Abstract] [Full Text] [Related]

  • 9. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P.
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [Abstract] [Full Text] [Related]

  • 10. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N, Horiguchi K, Nishioka H, Suzuki H, Takeshita A, Takeuchi Y, Inoshita N, Yamada S.
    Endocr J; 2015 Aug; 62(1):21-7. PubMed ID: 25273395
    [Abstract] [Full Text] [Related]

  • 11. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
    [Abstract] [Full Text] [Related]

  • 12. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
    Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K.
    Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
    [Abstract] [Full Text] [Related]

  • 13. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
    Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, Harris AG.
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
    [Abstract] [Full Text] [Related]

  • 14. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S.
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [Abstract] [Full Text] [Related]

  • 15. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients.
    Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A.
    Eur J Endocrinol; 2003 Apr; 148(4):433-42. PubMed ID: 12656664
    [Abstract] [Full Text] [Related]

  • 16. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
    Gatto F, Barbieri F, Castelletti L, Arvigo M, Pattarozzi A, Annunziata F, Saveanu A, Minuto F, Castellan L, Zona G, Florio T, Ferone D.
    Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
    [Abstract] [Full Text] [Related]

  • 17. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A, Cakyr B, Azal O, Corakcy A, Kutlu M, Oezata M.
    Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
    [Abstract] [Full Text] [Related]

  • 18. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
    Chanson P, Weintraub BD, Harris AG.
    Ann Intern Med; 1993 Aug 01; 119(3):236-40. PubMed ID: 8323093
    [Abstract] [Full Text] [Related]

  • 19. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA, Bernstein R, Chynn KY, Kourides IA.
    J Clin Endocrinol Metab; 1992 Mar 01; 74(3):690-4. PubMed ID: 1740506
    [Abstract] [Full Text] [Related]

  • 20. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM.
    Clin Endocrinol (Oxf); 1994 Mar 01; 40(3):421-8. PubMed ID: 8187308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.